Companies in #Solid Tumors

ADC Therapeutics is a commercial-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for the treatment of hematologic cancers and solid tumors. Its lead product Zynlonta (loncastuximab tesirine) is the first CD19-targeted ADC approved for relapsed/refractory diffuse large B-cell lymphoma. The company is advancing a pipeline of next-generation ADCs targeting both hematologic malignancies and selected solid tumors.

MacroGenics is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-based therapeutics for cancer. Its proprietary DART and TRIDENT bispecific platforms enable multi-specific targeting, and the company has one approved HER2-targeted breast cancer drug, Margenza (margetuximab-cmkb).

Tubulis is a biotechnology company developing a new generation of antibody-drug conjugates (ADCs) for the treatment of cancer. Its proprietary platforms — Tub-tag, P5 conjugation, and Topoisomerase-I inhibitor payloads — enable the design of highly stable, targeted ADCs with improved therapeutic index. In May 2026, Gilead Sciences completed the acquisition of Tubulis for up to $5 billion ($3.15B cash upfront + $1.85B milestones).